mavacamten
mavacamten: 11 clinical trials tracked.
mavacamten evidence translation
What we can confirm
11 tracked trials
What it means
What to watch
Prepared research question
What is verified about mavacamten, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (11)showing 10 most recent
Real-world Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Number of participants in each study cohort
A Study Evaluating Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Cibenzoline in Japan (MANAGE-HCM)
Primary endpoint: Change in either resting or Valsalva Left Ventricular Outflow Tract (LVOT) peak gradient whichever used to judge the initiation of mavacamten treatment
A Single-Arm Observational Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
Primary endpoint: Change from baseline in Valsalva left ventricular outflow tract (LVOT) gradient
Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community
Primary endpoint: Participant blood pressure (both systolic and diastolic)
A Phase 4, Single-Arm, Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy in India
Primary endpoint: Incidence of serious Treatment Emergent Adverse Events (TEAEs)
Patient Characteristics and Treatment Duration of Mavacamten Obstructive HCM Patient Support Program in Canada: A Retrospective Cohort Study
Primary endpoint: Participant demographics
MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)
Primary endpoint: Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48
MavAcamten Real World eVidEnce coLlaboration in HCM (MARVEL-HCM)
Primary endpoint: New York Heart Association (NYHA) functional class
mavaCamten ObservationaL evIdence Global cOnsortium in HCM (COLLIGO-HCM)
Primary endpoint: Participant age at Hypertrophic Cardiomyopathy (HCM) diagnosis
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Change From Baseline in KCCQ-23 CSS at Week 48